Drug intelligence / Profile preview

SBT-101

Development stage: Preclinical
Lead developer: Freeline Therapeutics
Administration: Intrathecal

Overview

SBT-101 is a STING (Stimulator of interferon genes) antagonist developed by Silverback Therapeutics. It is being investigated for the treatment of autoimmune and inflammatory diseases. Silverback Therapeutics, a clinical-stage biopharmaceutical company, merged with ARS Pharmaceuticals in a reverse merger, with the intention of creating a more diversified company focused on immunology by combining Silverback's pipeline, which includes SBT-101, with ARS Pharma's pipeline.

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on SBT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT-101.

Explore the full profile